eFFECTOR Therapeutics
Protein Translation Inhibitors for Oncology

eFFECTOR Therapeutics is pioneering a new class of therapeutics known as selective translation regulators (STRs). By acting on key biological mechanisms responsible for tumor growth and immune suppression, STRs represent a promising small molecule approach for fighting cancer. Their most advanced program, tomivosertib (eFT508), is currently in multiple Phase 2 clinical trials for the treatment of several types of cancer, both as an immune modulator and as an agent that acts directly on tumor cells.

 

 


University
UC San Francisco
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website